Clinical analysis of patients received pemetrexed therapy without the advised folic acid premedication
10.3969/j.issn.1006-5725.2015.07.044
- VernacularTitle:培美曲塞治疗未提前补充叶酸的晚期非小细胞肺癌35例
- Author:
Liang YE
;
Zhenhua YANG
;
Surong FANG
;
Yan TAN
;
Wei GU
- Publication Type:Journal Article
- Keywords:
Folic acid;
Pemetrexed;
Adverse events
- From:
The Journal of Practical Medicine
2015;(7):1176-1179
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore whether 5 to -7-day of folic acid supplementation prior to pemetrexed therapy is needed. Methods We retrospectively evaluate the outcomes of non-small cell lung cancer patients received less than the advised folic acid premedication. Seventy patients with Ⅲ-Ⅳ NSCLC were randomly divided into two groups: patients who initiated vitamin supplementation on 7 days before the first dose of pemetrexed (group A) and patients who initiated vitamin supplementation on the day of the first dose of pemetrexed (group B). Results In group A and group B, CR 0 and 0, PR 10 and 8, the response rates of 28.6% and 22.9% were observed, respectively. There was no statistically significant differences between these two groups. No significant differences were observed in the incidence of hematologic and non-hematologic toxicities. Conclusions The initiation of pemetrexed-based chemotherapy does not need to accommodate a vitamin supplementation schedule.
